Dublin, July 03, 2025 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Therapeutics), Application (Cardiology, Neurology, Oncology), End-use (Hospitals, Diagnostic Centers), and Region with Growth Forecasts, 2025-2030" has been added to ResearchAndMarkets.com's offering.
The Nuclear Medicine Market was valued at USD 17.77 billion in 2024, and is projected to reach USD 34.51 billion by 2030, rising at a CAGR of 10.16%. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer. 
Nuclear Medicine Market Report Highlights
- By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
- The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
- By application, the oncology segment dominated the market in 2024.
- North America dominated the market with a share of 42.87% in 2024, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
- The Asia-Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.
According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.
Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency's (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.
In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 170 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $17.77 Billion |
| Forecasted Market Value (USD) by 2030 | $34.51 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
Key Topics Covered
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and Application Outlook
2.2.2. End Use Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights
Chapter 3. Nuclear Medicine Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Cancer and Cardiovascular Diseases
3.2.1.2. Increasing Application of Radiopharmaceuticals/Nuclear Medicine
3.2.1.3. Growing Demand for Accurate Diagnostic Methods
3.2.2. Market Restraint Analysis
3.2.2.1. High Cost of Treatment
3.2.2.2. Stringent Regulations Pertaining to Production, Storage, & Usage
3.3. Nuclear Medicine Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
3.3.3. Pipeline Analysis
Chapter 4. Nuclear Medicine Market: Product Estimates & Trend Analysis
4.1. Global Nuclear Medicine Market: Product Dashboard
4.2. Global Nuclear Medicine Market: Product Movement Analysis
4.3. Global Nuclear Medicine Market by Product, Revenue
4.4. Diagnostics
4.5. Therapeutics
Chapter 5. Nuclear Medicine Market: Application Estimates & Trend Analysis
5.1. Global Nuclear Medicine Market: Application Dashboard
5.2. Global Nuclear Medicine Market: Application Movement Analysis
5.3. Global Nuclear Medicine Market Estimates and Forecasts, by Application, Revenue (USD Million)
5.4. Cardiology
5.5. Neurology
5.6. Oncology
5.7. Thyroid
5.8. Lymphoma
5.9. Bone Metastasis
5.10. Endocrine Tumor
5.11. Pulmonary Scans
5.12. Urology
5.13. Others
Chapter 6. Nuclear Medicine Market: End Use Estimates & Trend Analysis
6.1. Global Nuclear Medicine Market: End Use Dashboard
6.2. Global Nuclear Medicine Market: End Use Movement Analysis
6.3. Global Nuclear Medicine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
6.4. Hospitals
6.5. Diagnostic Centers
6.6. Others
Chapter 7. Nuclear Medicine Market: Regional Estimates & Trend Analysis by Product, Application, and End Use
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.3. North America
7.4. Europe
7.5. Asia-Pacific
7.6. Latin America
7.7. MEA
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of Key Distributors and Channel Partners
8.3.2. Key Customers
8.3.3. Key Company Market Share Analysis, 2024
8.3.4. GE Healthcare
8.3.5. Jubilant Life Sciences Ltd.
8.3.6. Nordion (Canada), Inc.
8.3.7. Bracco Imaging S.p.A.
8.3.8. The Institute for Radioelements (IRE)
8.3.9. NTP Radioisotopes SOC Ltd.
8.3.10. The Australian Nuclear Science and Technology Organization
8.3.11. Eczacibasi-Monrol
8.3.12. Lantheus Medical Imaging, Inc.
8.3.13. Eckert & Ziegler
8.3.14. Mallinckrodt
8.3.15. Cardinal Health
For more information about this report visit https://www.researchandmarkets.com/r/elds82
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
